Efficacy of rimonabant in obese patients with binge eating disorder

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 1, 2013, Pages 20-26

  Pataky, Z ^a   Gasteyger, C ^a   Ziegler, O ^b   Rissanen, A ^c   Hanotin, C ^d   Golay, A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Ctr Hospitalier Univ de Nancy   (France)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d SANOFI   (France)

Author keywords

binge eating disorder; endocannabinoid system; obesity; rimonabant

Indexed keywords

PLACEBO; RIMONABANT;

ADULT; AGED; ANXIETY; ARTICLE; BINGE EATING DISORDER; BODY WEIGHT; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; AGED; BINGE-EATING DISORDER; CANNABINOID RECEPTOR ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES; WEIGHT LOSS;

EID: 84872605604     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1329957     Document Type: Article

References (52)

1. Engeli S., Bohnke J., Feldpausch M. et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes: 2005; 54 2838 2843 (Pubitemid 41401077)
2. Bluher M., Engeli S., Kloting N. et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes: 2006; 55 3053 3060 (Pubitemid 44923642)
3. Cote M., Matias I., Lemieux I. et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond): 2007; 31 692 699 (Pubitemid 46482358)
4. Sipe J. C., Scott T. M., Murray S. et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS One: 2010; 5 e8792
5. Rosenson R. S. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology: 2009; 114 212 225
6. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci: 2005; 8 585 589 (Pubitemid 40594198)
7. Van Gaal L. F., Rissanen A. M., Scheen A. J. et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet: 2005; 365 1389 1397 (Pubitemid 40523733)
8. Pi-Sunyer F. X., Aronne L. J., Heshmati H. M. et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA: 2006; 295 761 775 (Pubitemid 43244304)
9. Despres J. P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med: 2005; 353 2121 2134 (Pubitemid 41653104)
10. Scheen A. J., Finer N., Hollander P. et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet: 2006; 368 1660 1672 (Pubitemid 46048528)
11. Kunnas T., Lahtio R., Kortelainen M. L. et al. Gln27Glu variant of Beta2-adrenoceptor gene affects male type fat accumulation in women. Lipids Health Dis: 2009; 8 43
12. Silvestri C., Di Marzo V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs: 2012
13. Triay J., Mundi M., Klein S. et al. Does rimonabant independently affect free fatty acid and glucose metabolism? J Clin Endocrinol Metab: 2012; 97 819 827
14. Christou G. A., Tellis C. C., Elisaf M. S. et al. The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment. Angiology: 2012; 63 67 75
15. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (Text Revision). Washington, DC American Psychiatric Press: 2000
16. Monteleone P., Matias I., Martiadis V. et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology: 2005; 30 1216 1221 (Pubitemid 40720981)
17. Williams C. M., Kirkham T. C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl): 1999; 143 315 317 (Pubitemid 29204987)
18. Jamshidi N., Taylor D. A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol: 2001; 134 1151 1154 (Pubitemid 33097243)
19. Arias Horcajadas F. Cannabinoids in eating disorders and obesity. Mol Neurobiol: 2007; 36 113 128 (Pubitemid 351360350)
20. Parylak S. L., Cottone P., Sabino V. et al. Effects of CB(1) and CRF(1) receptor antagonists on binge-like eating in rats with limited access to a sweet fat diet: Lack of withdrawal-like responses. Physiol Behav: 2012; 107 231 242
21. de Zwaan M. Binge eating disorder and obesity. Int J Obes Relat Metab Disord: 2001; 25 01 S51 S55 (Pubitemid 32565157)
22. Yanovski S. Z. Binge eating disorder and obesity in 2003: could treating an eating disorder have a positive effect on the obesity epidemic? Int J Eat Disord: 2003; 34 Suppl S117 S120 (Pubitemid 36935719)
23. Hodge A. M., Zimmet P. Z. The epidemiology of obesity. Baillieres Clin Endocrinol Metab: 1994; 8 577 599 (Pubitemid 24246208)
24. Pataky Z., Carrard I., Golay A. Psychological factors and weight loss in bariatric surgery. Curr Opin Gastroenterol: 2011; 27 167 173
25. Reas D. L., Grilo C. M. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring): 2008; 16 2024 2038
26. Spitzer R. L., Yanovski S. Z., Marcus M. D. Questionnaire on Eating and Weight Patterns-Revised. Mc Lean, VA BRS Search Service: 1994
27. Elder K. A., Grilo C. M., Masheb R. M. et al. Comparison of two self-report instruments for assessing binge eating in bariatric surgery candidates. Behav Res Ther: 2006; 44 545 560 (Pubitemid 43220454)
28. Celio A. A., Wilfley D. E., Crow S. J. et al. A comparison of the binge eating scale, questionnaire for eating and weight patterns-revised, and eating disorder examination questionnaire with instructions with the eating disorder examination in the assessment of binge eating disorder and its symptoms. Int J Eat Disord: 2004; 36 434 444 (Pubitemid 39587400)
29. WHO Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity, Geneva, June 3-5, 1997. Geneva WHO: 1998
30. Stunkard A. J., Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res: 1985; 29 71 83 (Pubitemid 15134378)
31. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res: 1998; 6 02 51S 209S
32. Bobbioni-Harsch E., Pataky Z., Makoundou V. et al. From metabolic normality to cardiometabolic risk factors in subjects with obesity. Obesity (Silver Spring): 2012; 20 2063 2069
33. Arnold L. M., McElroy S. L., Hudson J. I. et al. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry: 2002; 63 1028 1033 (Pubitemid 35388063)
34. Grilo C. M., Masheb R. M., Wilson G. T. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry: 2005; 57 301 309 (Pubitemid 40187375)
35. Devlin M. J., Goldfein J. A., Petkova E. et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res: 2005; 13 1077 1088
36. Hudson J. I., McElroy S. L., Raymond N. C. et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry: 1998; 155 1756 1762 (Pubitemid 28547503)
37. Pearlstein T., Spurell E., Hohlstein L. A. et al. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Womens Ment Health: 2003; 6 147 151 (Pubitemid 36565907)
38. McElroy S. L., Casuto L. S., Nelson E. B. et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry: 2000; 157 1004 1006 (Pubitemid 30412354)
39. McElroy S. L., Hudson J. I., Malhotra S. et al. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry: 2003; 64 807 813 (Pubitemid 36897217)
40. Grilo C. M., Masheb R. M., Salant S. L. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry: 2005; 57 1193 1201 (Pubitemid 40615782)
41. Golay A., Laurent-Jaccard A., Habicht F. et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res: 2005; 13 1701 1708
42. Makoundou V., Pataky Z., Bobbioni-Harsch E. et al. Multi-factorial approach associated with a new on/off Orlistat(R) use in a weight loss maintenance programme: 4 years follow-up. Obes Facts: 2011; 4 191 196
43. Appolinario J. C., Bacaltchuk J., Sichieri R. et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry: 2003; 60 1109 1116 (Pubitemid 37429650)
44. Wilfley D. E., Crow S. J., Hudson J. I. et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry: 2008; 165 51 58 (Pubitemid 351704552)
45. Stunkard A., Berkowitz R., Tanrikut C. et al. d-fenfluramine treatment of binge eating disorder. Am J Psychiatry: 1996; 153 1455 1459 (Pubitemid 26365461)
46. Claudino A. M., de Oliveira I. R., Appolinario J. C. et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry: 2007; 68 1324 1332 (Pubitemid 47524510)
47. McElroy S. L., Arnold L. M., Shapira N. A. et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry: 2003; 160 255 261 (Pubitemid 41110450)
48. McElroy S. L., Hudson J. I., Capece J. A. et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry: 2007; 61 1039 1048 (Pubitemid 46551975)
49. Brownley K. A., Berkman N. D., Sedway J. A. et al. Binge eating disorder treatment: a systematic review of randomized controlled trials. Int J Eat Disord: 2007; 40 337 348 (Pubitemid 46651308)
50. Marcus M. D., Wing R. R., Lamparski D. M. Binge eating and dietary restraint in obese patients. Addict Behav: 1985; 10 163 168 (Pubitemid 15009589)
51. Friederich H. C., Schild S., Wild B. et al. Treatment outcome in people with subthreshold compared with full-syndrome binge eating disorder. Obesity (Silver Spring): 2007; 15 283 287 (Pubitemid 46407308)
52. Grilo C. M., White M. A., Masheb R. M. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord: 2009; 42 228 234